The safety and contraceptive efficacy of a 24-day low-dose oral contraceptive regimen containing gestodene 60 μg and ethinylestradiol 15 μg

被引：0

作者：

Bocci, A. ^{[1
]}

Spielniann, D. ^{[1
]}

Azzini, Pr ^{[1
]}

Guaschino, Pr ^{[1
]}

Affronti, G. ^{[1
]}

Villani, Pr ^{[1
]}

Boselli, Pr ^{[1
]}

Genazzani, Pr ^{[1
]}

Flamigni, Z. C. ^{[1
]}

Omodei, U. ^{[1
]}

Bolis, P. ^{[1
]}

Marsoni, V. ^{[1
]}

Luerti, M. ^{[1
]}

Simenel, J. L. ^{[1
]}

Ouvry-Neveu, B. ^{[1
]}

Andre, G. ^{[1
]}

David, S. ^{[1
]}

Durand, J. L. ^{[1
]}

Ehret-Mentre, C. ^{[1
]}

Gensburger, J. M. ^{[1
]}

Goetzmann, P. ^{[1
]}

Jung-Faerber, S. ^{[1
]}

Keller, D. ^{[1
]}

Lempereur, M. ^{[1
]}

Plumere, C. ^{[1
]}

Spielmann, A. ^{[1
]}

Katz, J. L. ^{[1
]}

Sebaoun, J. ^{[1
]}

Belaisch, J. ^{[1
]}

Hammer, F. ^{[1
]}

Salama, B. ^{[1
]}

Aissaoui, S. ^{[1
]}

Taube, A. M. ^{[1
]}

Nakache, H. ^{[1
]}

Soria, J. ^{[1
]}

Joffo, M. ^{[1
]}

Lardenois, H. ^{[1
]}

Leclerc, P. ^{[1
]}

Ponsar, C. ^{[1
]}

Saubry-Bobet, V. ^{[1
]}

Blaiset, E. ^{[1
]}

Veyres, F. ^{[1
]}

Clamp, M. ^{[1
]}

Menon, K. V. K. ^{[1
]}

Moran, D. G. ^{[1
]}

Randall, S. ^{[1
]}

Shaw, P. J. ^{[1
]}

Bruni, V. ^{[1
]}

Massobrio, M. ^{[1
]}

Crosignani, P. ^{[1
]}

机构：

[1] Wyeth Ayersr Res, F-92031 Paris, France

来源：

EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE | 1999年 / 4卷

关键词：

Oral contraceptive; Contraceptive efficacy; Gestodene; Ethinylestradiol;

D O I：

暂无

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Objective The safety and contraceptive efficacy of a new 24-day regimen of an oral contraceptive combination containing gestodene (GTD) 60 mu g and ethinylestradiol (EE) 15 mu g was evaluated in an open-label, multicenter study. Methods Adult women received GTD 60 mu g/EE 15 mu g from day 1 to 24 and 4 days of placebo during a 28-day cycle for either 13 or 19 cycles. Results Of the 1515 subjects enrolled, 1496 were included in the intent-to-treat analysis. A total of three pregnancies were reported during the 18 194 treatment cycles of the study, yielding a Pearl index of 0.21. Life-table analysis, based on 16 954 cycles, gave an accidental pregnancy rate of 0.0033. The most frequent adverse events were headache (reported in 35% of subjects), absence of bleeding (16%), flu-like syndrome (15%), pharyngitis (15%) and abdominal pain (15%). The most frequent reasons for withdrawal from the study were metrorrhagia, flu syndrome and absence of bleeding. Analyses of withdrawal and intermenstrual bleeding and spotting indicated acceptable cycle control. Conclusions The 24-day GTD 60 mu g/EE 15 mu g, regimen appears to be a well-tolerated and effective method for low-dose oral contraception. The current formulation offers an ultra-low steroidal dosage combined with a reduced pill-free interval to improve contraceptive efficacy.

引用

页码：9 / 15

页数：7

共 50 条

[21] Prospective, open-label, noncomparative study to assess cycle control, safety and acceptability of a new oral contraceptive containing gestodene 60 μg and ethinylestradiol 15 μg (Minesse®)
Barbosa, IC
Isaia, C
Faggion, D
Baracat, EC
CONTRACEPTION, 2006, 73 (01) : 30 - 33
[22] Effects of two low dose monophasic oral contraceptives containing 15 μg ethinylestradiol/60 μg gestodene and 20 μg ethinylestradiol/150 μg desogestrel on serum lipids
Dessole, S
Tonolo, G
Alvau, S
Puddu, L
Todesco, MP
Brizzi, P
Maioli, M
Ambrosini, A
INFERTILITY AND ASSISTED REPRODUCTIVE TECHNOLOGY: FROM RESEARCH TO THERAPY, 1997, : 471 - 476
[23] CLINICAL TOLERANCE OF A COMBINED MONOPHASIC CONTRACEPTIVE AGENT CONTAINING A LOW-DOSE OF ETHINYLESTRADIOL AND GESTODENE IN ADOLESCENTS
LEONARD, F
GASPARD, U
THEUNISSEN, L
CURRENT MEDICAL RESEARCH AND OPINION, 1993, 13 (02) : 78 - 86
[24] Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 μg given for 24 days compared to a 21-day regimen.
Ellman, H
Archer, DF
FERTILITY AND STERILITY, 2005, 84 : S169 - S170
[25] Double-blind, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day versus a 21-day low-dose oral contraceptive regimen containing 20 μg ethinyl estradiol and 75 μg gestodene
Endrikat, J
Cronin, M
Gerlinger, C
Ruebig, A
Schmidt, W
Düsterberg, B
CONTRACEPTION, 2001, 64 (02) : 99 - 105
[26] Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 μg levonorgestrel and 20 μg ethinyl estradiol (Alesse®)
Archer, DF
Maheux, R
DelConte, A
O'Brien, FB
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1999, 181 (05) : S39 - S44
[27] INHIBITION OF OVULATION BY LOW-DOSE MONOPHASIC CONTRACEPTIVE CONTAINING GESTODENE
THOMAS, K
VANKRIEKEN, L
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1990, 163 (04) : 1404 - 1410
[28] METABOLIC EFFECTS OF A GESTODENE-CONTAINING LOW-DOSE ORAL-CONTRACEPTIVE PILL
RABE, T
RUNNEBAUM, B
GRUNWALD, K
KIESEL, L
HARENBERG, J
ZIMMERMANN, R
FIEHN, W
WEICKER, H
ADVANCES IN GYNECOLOGICAL ENDOCRINOLOGY, VOLS 1 AND 2, 1988, : B353 - B367
[29] Latin American experience with two low-dose oral contraceptives containing 30 μg ethinylestradiol/75 μg gestodene and 20 μg ethinylestradiol/150 μg desogestrel
Bassol, S
Alvarado, A
Celis, C
Cravioto, MC
Peralta, O
Montaño, R
Novelli, J
Albornoz, H
Kesseru, E
Soares, A
Petracco, A
Isaia, B
Mendes, J
Bahamondes, L
de Melo, NR
Reyes-Marquez, R
Albrecht, G
CONTRACEPTION, 2000, 62 (03) : 131 - 135
[30] The efficacy and safety of a low-dose, 91-day, extended-regimen oral contraceptive with continuous ethinyl estradiol
Kroll, Robin
Reape, Kathleen Z.
Margolis, Marya
CONTRACEPTION, 2010, 81 (01) : 41 - 48

← 1 2 3 4 5 →